Stay updated on Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Sign up to get notified when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.

Latest updates to the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page reflects a change in the site/system revision label, indicating an interface or platform version update without modifying the underlying clinical trial record details.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedAdded a Study Status entry and removed an older version date in the record history.SummaryDifference0.2%

- Check44 days agoChange DetectedRevision history updated to include v3.5.0 and remove v3.4.3. This appears to be a UI/backend update with no changes to study data or functionality.SummaryDifference0.1%

- Check59 days agoChange DetectedA new revision entry (v3.4.3) was added and the previous revision (v3.4.2) was removed in the study record history.SummaryDifference0.1%

- Check80 days agoChange DetectedA new revision entry (v3.4.2) was added and an older revision (v3.4.1) was removed. The latest version also includes the 'Study Status' section in the history view.SummaryDifference0.3%

- Check88 days agoChange DetectedThe history shows a new revision entry for v3.4.1 and the deletion of the previous revision v3.4.0. It reflects an administrative update to the page's revision history.SummaryDifference0.1%

Stay in the know with updates to Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.